RGEN Earnings Date: Feb 23, 2027 (Estimated) — Repligen Corporation
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is RGEN's next earnings date?
Repligen Corporation (RGEN) is expected to report Q4 2026 earnings on Tuesday, February 23, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.58 on revenue of $221.6M.
How did RGEN do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), Repligen Corporation posted EPS of $0.53 versus the $0.46 estimate, a beat of 14.5%. Revenue was $209.3M against a $206.7M estimate. The stock's 1-day post-earnings move was -2.4%.
How much does RGEN stock move after earnings?
RGEN beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About Repligen Corporation
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
🤖 AI Earnings Analysis
Repligen’s BioLife acquisition accelerates its bioprocessing leadership, while Q3 revenue grew 11% reported (12.5% organic) to $209M and EPS beat by $0.07 at $0.53. Strong results, though full-year guidance of $813M–$835M revenue and $2.03–$2.09 EPS should anchor expectations.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | 0.46 | 0.53 | +14.52% | $209.3M | ✅ Beat | -2.43% | — | — |
| 2026-07-28 | Q2 2026 | 0.45 | 0.54 | +20.00% | $204.1M | ✅ Beat | +10.90% | +12.21% | +38.63% |
| 2026-05-05 | Q1 2026 | 0.38 | 0.48 | +26.32% | $194.3M | ✅ Beat | +6.26% | -1.95% | +2.98% |
| 2026-02-24 | Q4 2025 | 0.44 | 0.49 | +11.36% | $197.9M | ✅ Beat | -0.54% | -7.70% | -14.11% |
| 2025-10-28 | Q3 2025 | 0.42 | 0.46 | +9.52% | $188.8M | ✅ Beat | -5.92% | -6.78% | +6.62% |
| 2025-07-29 | Q2 2025 | 0.39 | 0.37 | -5.13% | $182.0M | ❌ Miss | +4.72% | -2.63% | +0.70% |
| 2025-02-20 | Q4 2024 | 0.41 | 0.44 | +7.32% | $167.5M | ✅ Beat | +7.92% | +8.01% | -7.56% |
| 2024-11-12 | Q3 2024 | 0.33 | 0.43 | +30.30% | $154.9M | ✅ Beat | +6.51% | -11.54% | +11.28% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $204.1M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 100.0% | $204.1M | +11.9% | $174.0M | $169.1M | $182.3M | $188.8M |
| Royalty | 0.0% | $43K | +16.2% | — | $35K | $37K | $39K |
By region
Q3 FY18 · $49.5M total
| Segment | Share | Revenue | YoY | Q2 FY18 | Q3 FY18 |
|---|---|---|---|---|---|
| North America | 48.6% | $24.1M | — | $22.5M | $24.1M |
| Europe | 39.0% | $19.3M | — | $19.6M | $19.3M |
| Asia and Australia | 12.3% | $6.1M | — | $5.6M | $6.1M |
| All Other | 0.1% | $62K | — | $55K | $62K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.